Serial No. 10/516,578 Group No. 1648 Confirmation No. 5513

## **PCT**

# WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



#### INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7: C12P 21/06, C12N 7/04, 5/00, A61K 39/12

(11) International Publication Number:

WO 00/08131

700, C1214 7704, 5700, A01K 55/12

(43) International Publication Date:

17 February 2000 (17.02.00)

(21) International Application Number:

PCT/US99/17702

(22) International Filing Date:

4 August 1999 (04.08.99)

(30) Priority Data:

60/095,242 60/112,405 4 August 1998 (04.08.98) US 15 December 1998 (15.12.98) US

15 December 1998 (15.12.98) US

(71) Applicant (for all designated States except US): PURDUE RE-SEARCH FOUNDATION [US/US]; Office of Technology Transfer, 1063 Hovde Hall, West Lafayette, IN 47907 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): SANDERS, David, A. [US/US]; 324 Jefferson Drive, West Lafayette, IN 47906 (US). KUHN, Richard, John [US/US]; 7501 Amanda Lane, West Lafayette, IN 47906 (US). JEFFERS, Scott, A. [US/US]; 1945 Indian Trail Drive, West Lafayette, IN 47906 (US). SHARKEY, Curtis, Matthew [US/US]; Apartment 6, 1307 Columbia, Lafayette, IN 47901 (US). NORTH, Cynthia, Lin [US/US]; 3803 B Sickle Court, Lafayette, IN 47905 (US). FISCHBACH, Michael, A. [US/US]; 120 Pathway Lane, West Lafayette, IN 47906 (US).

(74) Agents: SCHWARTZ, Jason, J. et al.; Woodard, Emhardt, Naughton, Moriarty & McNett, Bank One Center/Tower, Suite 3700, 111 Monument Circle, Indianapolis, IN 46204 (US).

(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published

With international search report.

(88) Date of publication of the international search report:

2 June 2000 (02.06.00)

(54) Title: PSEUDOTYPED RETROVIRUSES AND STABLE CELL LINES FOR THEIR PRODUCTION

(57) Abstract

Cells that produce inventive pseudotyped retroviruses having a broad host range have been produced. In one aspect of the invention, the cells produce retroviruses pseudotyped with at least two different viral glycoproteins, such as togaviral glycoproteins. In alternative embodiments, the cells produce retroviruses pseudotyped with filoviral glycoproteins. Methods of producing the above–described cells, as well as the pseudotyped retroviruses thus produced, are also provided. In other embodiments, methods of screening agents effective in blocking viral entry into a cell, including filoviral entry or entry of viruses having at least two different viral glycoproteins disposed in their lipid bilayer, such as togaviruses, are provided. Moreover, methods of using the inventive pseudotyped retroviruses for introducing nucleotide sequences into target cells, and kits for forming the inventive pseudotyped retroviruses, are also provided.

#### • /

#### FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Annenia	FI	Finland	LT	Lithuania	SK	Słovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
ΑU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
ΛZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	ТJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
ВJ	Benin	1E	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Isracl	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iccland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	zw	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Licchtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

International application No. PCT/US99/17702

A. CLASCIFICATION OF SUBJECT MATTER  IPC(7) :C12P 21/06; C12N 7/04, 5/00; A61K 39/12  US CL :435/69.1, 236, 325; 424/199.1							
According to International Patent Classification (IPC) or to both national classification and IPC							
	LDS SEARCHED						
	ocumentation searched (classification system followe	d by classification symbols)					
U.S. :	435/69.1, 236, 325; 424/199.1						
Documentat	tion searched other than minimum documentation to the	e extent that such documents are included	in the fields searched				
Electronic d	lata base consulted during the international search (na	ame of data base and, where practicable	, search terms used)				
USPATFUL, MEDLINE, WEST							
C. DOCUMENTS CONSIDERED TO BE RELEVANT							
Category*	Citation of document, with indication, where ap	propriate, of the relevant passages	Relevant to claim No.				
Y	US 5,491,084 A (CHALFIE et al.) document.	13 February 1996, see entire	3-4				
Y	US 5,512,421 A (BURNS et al.) document.	30 April 1996, see entire	1-12				
Y	US 5,591,624 A (BARBER et al.) document.	07 January 1997, see entire	1-12				
Y	US 5,503,974 A (GRUBER et al.) document.	02 April 1996, see entire	1-12				
Y	US 5,723,287 A (RUSSELL et al.) document.	03 March 1998, see entire	1-12				
Y	US 5,278,056 A (BANK et al.) l document.	l January 1994, see entire	1-12				
X Further documents are listed in the continuation of Box C: See patent family annex.							
Special categories of cited documents:     T							
	cument defining the general state of the art which is not considered	date and not in conflict with the appli the principle or theory underlying the					
1	be of particular relevance  Ther document published on or after the international filing date	"X" document of particular relevance; the					
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other		considered novel or cannot be consider when the document is taken alone  "Y"  document of particular relevance; the					
*O* do	scial reason (as specified) cument referring to an oral disclosure, use, exhibition or other ans	"Y" document of particular relevance; the considered to involve an inventive combined with one or more other such being obvious to a person skilled in the control of the control of the control of particular relevance.	step when the document is a documents, such combination				
·P· do	cument published prior to the international filing date but later than priority date claimed	*& document member of the same patent	2-7				
Date of the actual completion of the international search  Date of mailing of the international search report							
25 JANU	ARY 2000	10FEB2000					
	nailing address of the ISA/US	Authorized officer					
Box PCT	ner of Patents and Trademarks	Jeffrey S. Parkin, Ph.D.	1 1				
Washington, D.C. 20231		Telephone No. (703) 308-0196	<del>/</del>				

International application No.
PCT/US99/17702

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No
Category	Channel of document, with indication, where appropriate of the contract of	
Y	US 5,185,440 A (DAVIS et al.) 09 February 1993, see entire document.	5-7
Y	LOPEZ, S. et al. Nucleocapsid-Glycoprotein Interactions Required for Assembly of Alphaviruses. J. Virol. March 1994, Vol. 68, No. 3, pages 1316-1323, see entire document.	5-7
Y	KUHN, R. J. et al. Chimeric Sindbis-Ross River Viruses to Study Interactions between Alphavirus Nonstructural and Structural Regions. J. Virol. November 1996, Vol. 70, No. 11, pages 7900-7909, see entire document.	5-7

International application No. PCT/US99/17702

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)				
This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:				
1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:				
Claims Nos.:  because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:				
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).				
Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)				
This International Searching Authority found multiple inventions in this international application, as follows:				
Please See Extra Sheet.				
·				
As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.				
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.				
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:				
4. X No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:				
Remark on Protest  The additional search fees were accompanied by the applicant's protest.  No protest accompanied the payment of additional search fees.				

International application No. PCT/US99/17702

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

Group I, claim(s) 1-12, drawn to a eukaryotic cell comprising nucleotide sequences encoding, inter alia, at least two different viral glycoproteins.

Group II, claim(s) 13-18, drawn to a eukaryotic cell comprising nucleotide sequences encoding, inter alia, a filoviral glycoprotein.

Group III, claim(s) 19-29, drawn to a method of producing a eukaryotic cell capable of producing pseudotyped retroviruses with two different viral glycoproteins.

Group IV, claim(s) 30-32, drawn to a method of producing a eukaryotic cell capable of producing pseudotyped retroviruses with a filoviral glycoprotein.

Group V. claim(s) 33-38, drawn to a pseudotyped retrovirus containing at least two different viral glycoproteins.

Group VI, claim(s) 39, drawn to a pseudotyped retrovirus containing a Marburg virus glycoprotein.

Group VII, claim(s) 40-43, drawn to a method of introducing a nucleotide sequence into a cell by transducing a cell with a pseudotyped retrovirus expressing at least two different viral glycoproteins.

Group VIII, claim(s) 44, drawn to a method of introducing a nucleotide sequence into a cell by transducing a cell with a pseudotyped retrovirus expressing a Marburg virus glycoprotein.

Group IX, claim(s) 45-49 and 51, drawn to a method of screening for agents effective in blocking viral entry employing a pseudotyped retrovirus expressing at least two different viral glycoproteins.

Group X, claim(s) 50, 52, and 54, drawn to a method of screening agents effective in blocking Marburg virus entry into a cell employing a pseudotyped retrovirus expressing a Marburg virus glycoprotein.

Group XI, claim(s) 53, drawn to a kit for forming pseudotyped retroviruses containing at least two different viral glycoproteins.

Group XII, claim(s) 55, drawn to a kit for forming psuedotyped retroviruses containing a Marburg virus glycoprotein.

The inventions listed as Groups I-XII do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: The claims are directed toward multiple products (e.g., eukaryotic cells, pseudotyped retroviral particles, kits) with different chemical structures/compositions and attendant features (e.g., expressing two different viral glycoproteins, expressing a single virus glycoprotein). The claims are also directed toward multiple methods (e.g., method of making a eukaryotic cell capable of producing retroviral pseudotypes, method of gene transduction employing pseudotyped retroviral particles, method of screening for putative antiviral agents) that employ different reagents, methodology steps, and accomplish different scientific objectives. Accordingly, the claims all lack a special technical feature and are directed toward different inventive concepts.